COMPOUNDS FOR ORGANIC LIGHT EMITTING DIODE MATERIALS

Abstract

Described herein are molecules for use in organic light emitting diodes comprising at least one moiety A, at least one moiety D, and at least one moiety B.

Claims

1. A molecule comprising at least one moiety A, at least one moiety D, and at least one moiety B wherein: D for each occurrence independently, is a monocyclic or fused polycyclic aryl or heteroaryl having between 5 and 20 atoms, optionally substituted with one or more substituents each independently selected from C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.6-C.sub.18 aryl, (5-20 atom) heteroaryl, C.sub.1-C.sub.6 alkoxy, amino, C.sub.1-C.sub.12 alkylamino, C.sub.1-C.sub.12 dialkylamino, C.sub.1-C.sub.12 diarylamino, C.sub.1-C.sub.12 diarylamino, OH, or oxo; A, for each occurrence independently, is CF.sub.3, CN, or a monocyclic or fused polycyclic aryl or heteroaryl having between 5 and 20 atoms, optionally substituted with one or more substituents independently selected from C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.6-C.sub.18 aryl, (5-20 atom) heteroaryl, C.sub.1-C.sub.6 alkoxy, C(O)C.sub.1-C.sub.3 haloalkyl, S(O.sub.2)H, NO.sub.2, CN, oxo, halogen, OH, or C.sub.6-C.sub.18 haloaryl; B, for each occurrence independently, is a saturated monocyclic or polycyclic carbocycle or heterocycle, or is phenyl, and is optionally substituted with one or more substituents selected from C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.6-C.sub.18 aryl, (5-20 atom) heteroaryl; provided that at least one occurrence of B is a saturated monocyclic or polycyclic carbocycle or heterocycle; each occurrence of A is covalently attached to at least one occurrence of B, each occurrence of D is covalently attached to at least one occurrence of B, and each occurrence of B is attached to at least two moieties selected, for each occurrence independently, from an occurrence of A, D, or B, such that one molecule is formed by the covalent attachments.

2. The molecule of claim 1, wherein at least one instance of B is cyclopentane, cyclobutane, or cyclopropane.

3. The molecule of claim 1, wherein at least one instance of B is tetrahydrofuran, 2,2-dimethyltetrahydrofuran, or azetidine.

4. The molecule of claim 1, wherein at least one instance of B is a C.sub.5-C.sub.20 tricyclic carbocycle.

5. The molecule of claim 4, wherein at least one instance of B is represented by the following structural formula: ##STR00279##

6. The molecule of claim 1, wherein at least one instance of B is represented by the following structural formula: ##STR00280## wherein each R.sup.b is independently selected from C.sub.1-C.sub.6 alkylene and is optionally substituted with one or more C.sub.1-C.sub.6 alkyl, and further wherein B may be attached to the other moieties in the molecule by a bond to any carbon therein.

7. The molecule of claim 6, wherein at least one instance of B is represented by one of the following structural formulas: ##STR00281##

8. The molecule of claim 6, wherein at least one instance of B is represented by the following structural formula ##STR00282## and further wherein the bonds by which B is attached to the other moieties in the molecule are indicated by wavy lines.

9. The molecule of claim 1, wherein B is represented by one of the following structural formulas: ##STR00283##

10. The molecule of claim 1, wherein B is represented by one of the following structural formulas: ##STR00284## and further wherein the bonds by which B is attached to the other moieties in the molecule are indicated by wavy lines.

11. The molecule of claim 1, wherein the molecule the formula (A).sub.m(B).sub.1(D).sub.p, and further wherein: m is an integer greater than or equal to 1; p is an integer greater than or equal to 1; and l is an integer greater than or equal to one.

12. The molecule of claim 1, wherein A and D, for each occurrence independently, are selected from list U1, U2, U3, U4, U5, U6, U7, U8, or U9.

13. The molecule of claim 1, having a structural formula selected from the structural formulas listed in Table 3, and further wherein the molecule is optionally substituted with one or more substituents selected from C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.6-C.sub.18 aryl, (5-20 atom) heteroaryl, C.sub.1-C.sub.6 alkoxy, amino, C.sub.1-C.sub.12 alkylamino, C.sub.1-C.sub.12 dialkylamino, C.sub.1-C.sub.12 diarylamino, C.sub.1-C.sub.12 diarylamino, C(O)C.sub.1-C.sub.3 haloalkyl, OH, S(O.sub.2)H, NO.sub.2, CN, oxo, halogen, or C.sub.6-C.sub.18 haloaryl.

14. The molecule of claim 13, wherein the optional substituents are selected from C.sub.1-C.sub.6 alkyl, OH, CN, halogen, a C.sub.6-C.sub.12 aryl, a 5-20 atom heteroaryl, N(R.sup.19).sub.2, or N(R.sup.20).sub.2, wherein each R.sup.19, independently, is H or a C.sub.1-C.sub.6 alkyl, or a C.sub.5-C.sub.12 cycloalkyl, and wherein each R.sup.20, independently, is H or a C.sub.6-C.sub.18 aryl.

15. The molecule of claim 14, wherein the optional substituents are selected from C.sub.1-C.sub.6 alkyl or phenyl.

16. The molecule of claim 1, having a structural formula selected from the structural formulas listed in Table 2, and further wherein X is selected from C.sub.1-C.sub.6 alkyl, OH, CN, a halo, a C.sub.6-C.sub.12 aryl, a 5-20 atom heteroaryl, N(R.sup.19).sub.2, or N(R.sup.20).sub.2, wherein each R.sup.19, independently, is H or a C.sub.1-C.sub.6 alkyl, or a C.sub.5-C.sub.12 cycloalkyl, and wherein each R.sup.20, independently, is H or a C.sub.6-C.sub.18 aryl.

17. The molecule of claim 16, wherein the optional substituents are selected from C.sub.1-C.sub.6 alkyl or phenyl.

18. The molecule of claim 1, wherein each occurrence of A, D, and B is unsubstituted.

19. The molecule of claim 13, having a structural formula selected from the structural formulas listed in Table 3.

20. An organic light-emitting device containing: a first electrode; a second electrode; and an organic layer disposed between the first electrode and the second electrode, wherein the organic layer comprises at least one molecule as defined by claim 1.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0010] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawings will be provided by the Office upon request and payment of the necessary fee.

[0011] The foregoing will be apparent from the following more particular description of example embodiments of the invention, as illustrated in the accompanying drawings in which like reference characters refer to the same parts throughout the different views. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating embodiments of the present invention.

[0012] FIGS. 1 to 19 represent Table 3, which lists example embodiments of the present invention and their properties.

DETAILED DESCRIPTION OF THE INVENTION

[0013] In some embodiments, the present invention is one of the compounds shown in Table 3. In exemplary embodiments, the present invention is one of the compounds shown in Table 1.

[0014] In some embodiments, the present invention is an organic light-emitting device comprising a first electrode, a second electrode, and an organic layer between the first electrode and the second electrode. The organic layer comprises at least one light-emitting molecule selected from the molecules described herein. In certain embodiments, the organic layer comprises at least one light-emitting molecule selected from the molecules described in the twelfth aspect as described below. In certain embodiments, the organic layer comprises at least one light-emitting molecule selected from the molecules listed in Table 3. In exemplary embodiments, the organic layer comprises at least one light-emitting molecule selected from the molecules listed in Table 1.

Glossary

[0015] The term alkyl, as used herein, refers to a saturated aliphatic branched or straight-chain monovalent hydrocarbon radical having the specified total number of carbon atoms. Thus, C.sub.1-C.sub.6 alkyl means a radical having from 1-6 carbon atoms, inclusive of any substituents, in a linear or branched arrangement. Examples of C.sub.1-C.sub.6 alkyl include n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, n-pentyl, n-hexyl, 2-methylbutyl, 2-methylpentyl, 2-ethylbutyl, 3-methylpentyl, and 4-methylpentyl. An alkyl can be optionally substituted with halogen, OH, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6 alkoxy, NO.sub.2, CN, and N(R.sup.1)(R.sup.2) wherein R.sup.1 and R.sup.2 are each independently selected from H and C.sub.1-C.sub.3 alkyl.

[0016] The term alkenyl, as used herein, refers to a straight-chain or branched alkyl group having one or more carbon-carbon double bonds and having the specified total number of carbon atoms. Thus, C.sub.2-C.sub.6 alkenyl means a radical having 2-6 carbon atoms, inclusive of any substituents, in a linear or branched arrangement having one or more double bonds. Examples of C.sub.2-C.sub.6 alkenyl include ethenyl, propenyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, and hexadienyl. An alkenyl can be optionally substituted with the substituents listed above with respect to alkyl.

[0017] The term alkylene, as used herein, refers to a saturated group with two open valences, e.g., methylene, ethylene, or propylene. Thus, C.sub.1-C.sub.6 alkenyl means a diradical having 2-6 carbon atoms, inclusive of any substituents.

[0018] The term alkynyl, as used herein, refers to a straight-chain or branched alkyl group having one or more carbon-carbon triple bonds. Thus, C.sub.2-C.sub.6 alkynyl means a radical having 2-6 carbon atoms, inclusive of any substituents, in a linear or branched arrangement having one or more triple bonds. Examples of C.sub.2-C.sub.6 alkynyl include ethynyl, propynyl, butynyl, pentynyl, and hexynyl. An alkynyl can be optionally substituted with the substituents listed above with respect to alkyl.

[0019] The term cycloalkyl, as used herein, refers to a saturated monocyclic or fused polycyclic ring system containing from 3-12 carbon ring atoms. Saturated monocyclic cycloalkyl rings include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclooctyl. Saturated bicyclic and polycyclic cycloalkyl rings include, for example. norbornane, [2.2.2] bicyclooctane, decahydronaphthalene and adamantane. A cycloalkyl can be optionally substituted with the substituents listed above with respect to alkyl.

[0020] The term amino, as used herein, means an NH.sub.2, an NHR.sup.p, or an NR.sup.pR.sup.q, group, wherein R.sup.p and R.sup.q, each independently, can be C.sub.1-C.sub.12 alkyl, C.sub.2-C.sub.12 alkenyl, C.sub.2-C.sub.12 alkynyl, C.sub.2-C.sub.12 alkoxy, cycloalkyl, C.sub.6-C.sub.18 aryl, or 5-20 atom heteroaryl. Aminos may be primary (NH.sub.2), secondary (NHR.sub.p) or tertiary (NR.sub.pR.sub.q).

[0021] The term alkylamino, as used herein, refers to an NHR.sub.p, or an NR.sub.pR.sub.q group, wherein R.sub.p and R.sub.q can be alkyl, alkenyl, alkynyl, alkoxy, or cycloalkyl. The term dialkylamino, as used herein, refers to an NR.sub.pR.sub.q group, wherein R.sub.p and R.sub.q can be alkyl, alkenyl, alkynyl, alkoxy, or cycloalkyl.

[0022] The term alkoxy, as used herein, refers to an alkyl-O- group, wherein alkyl is defined above. Examples of alkoxy group include methoxy or ethoxy groups. The alkyl portion of alkoxy can be optionally substituted as described above with respect to alkyl.

[0023] The term aryl, as used herein, refers to an aromatic monocyclic or polycyclic ring system consisting of carbon atoms. Thus, C.sub.6-C.sub.18 aryl is a monocylic or polycyclic ring system containing from 6 to 18 carbon atoms. Examples of aryl groups include phenyl, indenyl, naphthyl, azulenyl, heptalenyl, biphenyl, indacenyl, acenaphthylenyl, fluorenyl, phenalenyl, phenanthrenyl, anthracenyl, cyclopentacyclooctenyl or benzocyclooctenyl. An aryl can be optionally substituted with halogen, OH, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6 haloalkyl, C.sub.1-C.sub.6 alkoxy, C.sub.6-C.sub.18 aryl, C.sub.6-C.sub.18 haloaryl, (5-20 atom) heteroaryl, -C(O)C.sub.1-C.sub.3 haloalkyl, C(O)-(C.sub.6-C.sub.18 aryl), S(O).sub.2, NO.sub.2, CN, and oxo. In an example embodiment, if an aryl is substituted with C.sub.6-C.sub.18 aryl, C.sub.6-C.sub.18 haloaryl, or (5-20 atom) heteroaryl, those substituents are not themselves substituted with C.sub.6-C.sub.18 aryl, C.sub.6-C.sub.18 haloaryl, or (5-20 atom) heteroaryl.

[0024] The terms halogen, or halo, as used herein, refer to fluorine, chlorine, bromine, or iodine.

[0025] The term heteroaryl, as used herein, refers a monocyclic or fused polycyclic aromatic ring containing one or more heteroatoms, such as oxygen, nitrogen, or sulfur. For example, a heteroaryl can be a 5-20 atom heteroaryl. which means a 5 to 20 membered monocyclic or fused polycyclic aromatic ring containing at least one heteroatom. Examples of heteroaryl groups include pyridinyl, pyridazinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, quinolyl, isoquinolyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, purinyl, oxadiazolyl, thiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzotriazolyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, dihydroquinolyl, tetrahydroquinolyl, dihydroisoquinolyl, tetrahydroisoquinolyl, benzofuryl, furopyridinyl, pyrolopyrimidinyl, and azaindolyl. A heteroaryl can be optionally substituted with the same substituents listed above with respect to aryl.

[0026] In other em embodiments, a 5-20 member heteroaryl refers to a fused polycyclic ring system wherein aromatic rings are fused to a heterocycle. Examples of these heteroaryls include:

##STR00001## ##STR00002## ##STR00003## ##STR00004##

[0027] The term haloalkyl, as used herein, includes an alkyl substituted with one or more of F, Cl, Br, or I, wherein alkyl is defined above. The alkyl portion of haloalkyl can be optionally substituted as described above with respect to alkyl.

[0028] The term haloaryl, as used herein, includes an aryl substituted with one or more of F, Cl, Br, or I, wherein aryl is defined above. The aryl portion of haloaryl can be optionally substituted as described above with respect to aryl.

[0029] The term oxo, as used herein, refers to O.

[0030] The term nitro, as used herein, refers to NO.sub.2.

[0031] The term symmetrical molecule, as used herein, refers to molecules that are group symmetric or synthetic symmetric. The term group symmetric, as used herein, refers to molecules that have symmetry according to the group theory of molecular symmetry. The term synthetic symmetric, as used herein, refers to molecules that are selected such that no regioselective synthetic strategy is required.

[0032] The term donor, as used herein, refers to a molecular fragment that can be used in organic light emitting diodes and is likely to donate electrons from its highest occupied molecular orbital to an acceptor upon excitation. In an example embodiment, donors have an ionization potential greater than or equal to 6.5 eV.

[0033] The term acceptor, as used herein, refers to a molecular fragment that can be used in organic light emitting diodes and is likely to accept electrons into its lowest unoccupied molecular orbital from a donor that has been subject to excitation. In an example embodiment, acceptors have an electron affinity less than or equal to 0.5 eV.

[0034] The term bridge, as used herein, refers to a molecular fragment that can be included in a molecule which is covalently linked between acceptor and donor moieties. The bridge can, for example, be further conjugated to the acceptor moiety, the donor moiety, or both. Without being hound to any particular theory, it is believed that the bridge moiety can sterically restrict the acceptor and donor moieties into a specific configuration, thereby preventing the overlap between the conjugated system of donor and acceptor moieties. Examples of suitable bridge moieties include phenyl, ethenyl, and ethynyl.

[0035] The terms acceptor, donor and bridge are applied to fragments of a single molecule based on their relative electronic properties. A molecular fragment can be a donor in one molecule, but an acceptor in another molecule.

[0036] The term multivalent, as used herein, refers to a molecular fragment that is connected to at least two other molecular fragments. For example, a bridge moiety is multivalent.

[0037] as used herein, refers to a point of attachment between two atoms.

Principles of OLED

[0038] OLEDs are typically composed of a layer of organic materials or compounds between two electrodes, an anode and a cathode. The organic molecules are electrically conductive as a result of delocalization of electronics caused by conjugation over part or all of the molecule. When voltage is applied, electrons from the highest occupied molecular orbital (HOMO) present at the anode flow into the lowest unoccupied molecular orbital (LUNO) of the organic molecules present at the cathode. Removal of electrons from the HOMO is also referred to as inserting electron holes into the HOMO. Electrostatic forces bring the electrons and the holes towards each other until they recombine and form an exciton (which is the bound state of the electron and the hole). As the excited state decays and the energy levels of the electrons relax, radiation is emitted having a frequency in the visible spectrum. The frequency of this radiation depends on the band gap of the material, which is the difference in energy between the HOMO and the LIMO.

[0039] As electrons and holes are fermions with half integer spin, an exciton may either be in a singlet state or a triplet state depending on how the spins of the electron and hole have been combined. Statistically, three triplet excitons will be formed for each singlet exciton. Decay from triplet states is spin forbidden, which results in increases in the timescale of the transition and limits the internal efficiency of fluorescent devices. Phosphorescent organic light-emitting diodes make use of spin-orbit interactions to facilitate intersystem crossing between singlet and triplet states, thus obtaining emission from both singlet and triplet states and improving the internal efficiency.

[0040] The prototypical phosphorescent material is iridium tris(2-phenylpyridine) (Ir(ppy).sub.3) in which the excited state is a charge transfer from the Ir atom to the organic ligand. Such approaches have reduced the triplet lifetime to about 1 s, several orders of magnitude slower than the radiative lifetimes of fully-allowed transitions such as fluorescence. Ir-based phosphors have proven to be acceptable for many display applications, but losses due to large triplet densities still prevent the application of OLEDs to solid-state lighting at higher brightness.

[0041] Further, recent research suggests that traditional Iridium based OLEDs may have reached a physical performance limit. The brightness of an OLED will decrease as the time of decay increases. Since the highest energy triplet state is the origin of the luminescent transition, increasing the zero-field splitting through additional spin-orbit coupling will eventually lengthen the effective lifetime of the other two triplets. It is believed that this effect is responsible for the asymptote empirically observed at about 1 s.

[0042] The recently developed thermally activated delayed fluorescence (TADF) seeks to minimize energetic splitting between singlet and triplet states (). The reduction in exchange splitting from typical values of 0.4-0.7 eV to a gap of the order of the thermal energy (proportional to k.sub.BT, where k.sub.B represents the Boltzmann constant, and T represents temperature) means that thermal agitation can transfer population between singlet levels and triplet sublevels in a relevant timescale even if the coupling between states is small.

[0043] Example TADF molecules consist of donor and acceptor moieties connected directly by a covalent bond or via a conjugated linker (or bridge). A donor moiety is likely to transfer electrons from its HOMO upon excitation to the acceptor moiety. An acceptor moiety is likely to accept the electrons from the donor moiety into its LUMO. The donor-acceptor nature of TADF molecules results in low-lying excited states with charge-transfer character that exhibit very low . Since thermal molecular motions can randomly vary the optical properties of donor-acceptor systems, a rigid three-dimensional arrangement of donor and acceptor moieties can be used to limit the non-radiative decay of the charge-transfer state by internal conversion during the lifetime of the excitation.

[0044] It is beneficial, therefore, to decrease energetic splitting between singlet and triplet states (), and to create a system with increased reversed intersystem crossing (RISC) capable of exploiting triplet excitons. Such a system, it is believed, will result in decreased emission lifetimes. Systems with these features will be capable of emitting blue light without being subject to the rapid degradation prevalent in blue OLEDs known today.

Compounds of the Invention

[0045] The molecules of the present invention, when excited via thermal or electronic means, can produce light in the blue or green region of the visible spectrum. The molecules comprise molecular fragments including at least one donor moiety, at least one acceptor moiety, and optionally, a bridge moiety.

[0046] Electronic properties of the example molecules of the present invention can be computed using known ab initio quantum mechanical computations. By scanning a library of small chemical compounds for specific quantum properties, molecules can be constructed which exhibit the desired spin-orbit/thermally activated delayed fluorescence (SO/TADF) properties described above.

[0047] It could be beneficial, for example, to build molecules of the present invention using molecular fragments with a calculated triplet state above 2.75 eV. Therefore, using a time-dependent density functional theory using, as a basis set, the set of functions known as 6-31G* and a Becke, 3-parameter, Lee-Yang-Parr hybrid functional to solve Hartree-Fock equations (TD-DFT/B3LYP/6-31G*), molecular fragments (moieties) can be screened which have HOMOs above a specific threshold and LUMOs below a specific threshold, and wherein the calculated triplet state of the moieties is above 2.75 eV.

[0048] Therefore, for example, a donor moiety (D) can be selected because it has a HOMO energy (e.g., an ionization potential) of greater than or equal to 6.5 eV. An acceptor moiety (A) can be selected because it has, for example, a LUMO energy (e.g., an electron affinity) of less than or equal to 0.5 eV. The bridge moiety (B) can be a rigid conjugated or saturated system which can, for example, sterically restrict the acceptor and donor moieties into a specific configuration, thereby preventing the overlap between the conjugated system of donor and acceptor moieties.

[0049] Accordingly, in a first aspect, the present invention is a molecule comprising at least one acceptor moiety A, at least one donor moiety D, and at least one bridge moiety B, wherein:

[0050] The moiety D, for each occurrence independently, is a monocyclic or fused polycyclic aryl or heteroaryl having between 5 and 20 atoms, optionally substituted with one or more substituents. In certain embodiments, the optional substituents on D, for each occurrence independently, are selected from C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.6-C.sub.18 aryl, (5-20 atom) heteroaryl, C.sub.1-C.sub.6 alkoxy, amino, C.sub.1-C.sub.12 alkylamino, C.sub.1-C.sub.12 dialkylamino, C.sub.1-C.sub.12 diarylamino, C.sub.1-C.sub.12 diarylamino, OH, or oxo.

[0051] The moiety A, for each occurrence independently, is CF.sub.3. CN, or a monocyclic or fused polycyclic aryl or heteroaryl having between 5 and 20 atoms, optionally substituted with one or more substituents. In certain embodiments, the optional substituents on A, for each occurrence independently, are selected from C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.6-C.sub.18 aryl, (5-20 atom) heteroaryl, C.sub.1-C.sub.6 alkoxy, C(O)C.sub.1-C.sub.3 haloalkyl, S(O.sub.2)H, NO.sub.2, CN, oxo, halogen, OH, or C.sub.6-C.sub.18 haloaryl.

[0052] The moiety B, for each occurrence independently, is a saturated monocyclic or polycyclic carbocycle or heterocycle, or is phenyl, and is optionally substituted with at least one substituent selected from C.sub.1-C.sub.6 alkyl or phenyl; provided that at least one occurrence of B is a saturated monocyclic or polycyclic carbocycle or heterocycle. In certain embodiments, the optional substituents on B, for each occurrence independently, are selected from C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.6-C.sub.18 aryl, (5-20 atom) heteroaryl.

[0053] Each moiety A is covalently attached to at least one moiety B, each moiety D is covalently attached to at least one moiety B, and each moiety B is attached to at least two moieties independently selected from A, D, or B, such that one molecule is formed by the covalent attachments. In an example embodiment of the first aspect, the molecule so formed is represented by the structure A-B-D. In another example embodiment of the first aspect, the molecule so formed is represented by the structure A-B-A-B-D. In another example embodiment of the first aspect, the moieties A are different than the moieties D.

[0054] In certain embodiments, B is monocyclic, such as cyclopentane, cyclobutane, or cyclopropane.

[0055] In certain embodiments, B is heterocyclic, such as tetrahydrofuran, 2,2-dimethyltetrahydrofuran, or azetidine.

[0056] In certain embodiments, B is polycyclic, such as bicyclic or tricyclic.

[0057] In certain embodiments, B is a bicyclo[a,b,c]alkane, wherein a, b, and c are independently selected from an integer greater than or equal to zero.

[0058] In certain embodiments, B is represented by the following structural formula:

##STR00005##

wherein each R.sup.b is independently selected from C.sub.1-C.sub.6 alkylene and is optionally substituted with one or more C.sub.1-C.sub.6 alkyl. B may be attached to the other moieties in the molecule by a bond to any carbon of B. In preferred embodiments, each R.sup.b is independently selected from methylene or ethylene and is optionally substituted with one or more C.sub.1-C.sub.6 alkyl.

[0059] In preferred embodiments, the bridges of formula B are selected from the following moieties:

##STR00006##

[0060] In certain embodiments, B is represented by the following structural formula:

##STR00007##

wherein the points of attachment to the other moieties in the molecule are indicated by the bonds interrupted with wavy lines.

[0061] In certain embodiments, B is tricyclic, such as the following moiety:

##STR00008##

[0062] In certain embodiments, B is represented by one of the following structural formulas:

##STR00009##

In certain embodiments, B is represented by one of the following structural formulas:

##STR00010##

wherein the points of attachment to the other moieties in the molecule are indicated by the bonds interrupted with wavy lines.

[0063] The foregoing rules of connection mean that the moiety A cannot be connected to another moiety A, the moiety D cannot be connected to another moiety D, and that each moiety B is multivalent, and must be connected to at least two other moieties, either a moiety A, a moiety D, or a second moiety B. In some embodiments, no molecular fragment represented by A is the same as any molecular fragment represented by D.

[0064] In a second aspect, the present invention is a molecule comprising at least one acceptor moiety A, at least one donor moiety D, and at least one bridge moiety B, wherein A, D, and B are defined above with respect to the first aspect of the present invention. In addition to the moieties recited above in the first aspect, the moiety D can be N(C.sub.6-C.sub.18aryl).sub.2. In addition to the moieties recited above with respect to the first aspect, the moiety A, can be S(O).sub.2.

[0065] In a third aspect, the present invention is a molecule defined by the structural formula (V)

(A).sub.m(B).sub.1

(D).SUB.p .(V)

[0066] wherein A, B, and D are defined above with respect to the first and second aspects;

[0067] the moiety D, for each occurrence independently, is optionally substituted with one or more substituents each independently selected from C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.6-C.sub.18 aryl, (5-20 atom) heteroaryl, C.sub.1-C.sub.6 alkoxy, amino, C.sub.1-C.sub.3 alkylamino, C.sub.1-C.sub.3 dialkylamino, or oxo;

[0068] the moiety A, for each occurrence independently, is optionally substituted with one or more substituents independently selected from C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.6-C.sub.18 aryl, (5-20 atom) heteroaryl, C.sub.1-C.sub.6 alkoxy, C(O)C.sub.1-C.sub.3 haloalkyl, S(O.sub.2)H, NO.sub.2, CN, oxo, halogen, or C.sub.6-C.sub.18 haloaryl;

[0069] the moiety B, for each occurrence independently, is optionally substituted with one to four substituents, each independently selected from C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 afkynyl, C.sub.6-C.sub.18 aryl, or (5-20 atom) heteroaryl;

[0070] m is an integer greater than or equal to 1;

[0071] p is an integer greater than or equal to 1; and

[0072] l is an integer greater than or equal to one. In an example embodiment, 1 is 1 or 2.

[0073] In a fourth aspect, the present invention is a molecule defined by the structural formula (V)

(A).sup.m(B).sub.1 (D).sub.p (V)

[0074] wherein A, B, and D are defined above with respect to the first or second aspects of the present invention, and

[0075] the moiety D, for each occurrence independently, is optionally substituted, in addition to the substituents described above with respect to the third aspect of the present invention, with N(C.sub.6-C.sub.18 aryl).sub.2;

[0076] the moiety A, for each occurrence independently, is optionally substituted as described above with respect to the third aspect of the present invention;

[0077] the moiety B, for each occurrence independently, is optionally substituted as described above with respect to the third aspect of the present invention;

[0078] m is an integer greater than or equal to 1;

[0079] p is an integer greater than or equal to 1; and

[0080] l is an integer greater than or equal to one. In an example embodiment, 1 is 1 or 2.

[0081] In a fifth aspect, the present invention is molecule defined by the structural formula (V)

(A).sub.m(B).sub.1 (D).sub.p (V)

[0082] wherein A, B, and D are defined above with respect to the first and second aspects of the present invention, and

[0083] the moiety D, for each occurrence independently, is optionally substituted as described above with respect to the third and fourth aspects, and further wherein, each alkyl, alkenyl, alkynyl, aryl, and heteroaryl optionally further substituted with one or more substituents selected from C.sub.1-C.sub.6 alkyl, 5-20 atom heteroaryl, or N(C.sub.6-C.sub.18aryl).sub.2;

[0084] the moiety A, for each occurrence independently, is optionally substituted as described above with respect to the third aspect of the present invention;

[0085] the moiety B, for each occurrence independently, is optionally substituted as described above with respect to the third aspect of the present invention;

[0086] m is an integer greater than or equal to 1;

[0087] p is an integer greater than or equal to 1; and

[0088] l is an integer greater than or equal to one. In an example embodiment, 1 is 1 or 2.

[0089] Structural formula (V) above can be linear or it can be branched.

[0090] In a sixth aspect, the present invention is a molecule as defined above with respect to the first or second aspects of the present invention, and wherein the moiety D, for each occurrence independently, can be selected from List D1.

##STR00011##

and wherein the moiety D can be optionally substituted as described above with respect to the third, fourth, and fifth aspects of the present invention.

[0091] In a seventh aspect, the present invention is a molecule as defined above with respect to the first or second aspects of the present invention, and wherein the moiety D, for each occurrence independently, can be selected from List D1, List D2, or both.

##STR00012## ##STR00013## ##STR00014## ##STR00015## ##STR00016## ##STR00017##

and wherein the moiety D can be optionally substituted as described above with respect to the third, fourth, and fifth aspects of the present invention.

[0092] In a eighth aspect, the present invention is a molecule as defined above with respect to the first or second aspects of the present invention, and wherein the moiety D, for each occurrence independently, can be selected from List D1, List D2, List D3, or any combination thereof.

##STR00018## ##STR00019## ##STR00020## ##STR00021## ##STR00022## ##STR00023## ##STR00024##

and wherein the moiety D can be optionally substituted as described above with respect to the third, fourth, and fifth aspects of the present invention.

[0093] In a ninth aspect, the present invention is a molecule as defined above with respect to the first or second aspects of the present invention, and wherein the moiety A, for each occurrence independently, can be selected from List A1.

##STR00025## ##STR00026## ##STR00027##

and wherein the moiety A can be optionally substituted as described above with respect to the third, fourth, and fifth aspects of the present invention.

[0094] In a tenth aspect, the present invention is a molecule as defined above with respect to the first, second, or third aspects of the present invention, and wherein the moiety A, for each occurrence independently, can be selected from List A1, List A2, or both.

##STR00028## ##STR00029## ##STR00030## ##STR00031##

and wherein the moiety A can be optionally substituted as described above with respect to the third, fourth, and fifth aspects of the present invention.

[0095] In a eleventh aspect, the present invention is a molecule as defined above with respect to the first or second aspects of the present invention, and wherein the moiety A, for each occurrence independently, can be selected from List A1, List A2, List A3, or any combination thereof.

##STR00032##

and wherein the moiety A can be optionally substituted as described above with respect to the third, fourth, and fifth aspects of the present invention.

[0096] In an example embodiment of the sixth aspect of the present invention, the moiety D, for each occurrence independently, is selected from List D4.

##STR00033## ##STR00034## ##STR00035##

wherein, within each molecule:

[0097] Q is the moiety A or a moiety B.sub.0-2-A and each M is the moiety A or the moiety B.sub.0-2-A, wherein

[0098] all groups Q are the same and all groups M are the same, and

[0099] each group Q is the same or different from any group M, and the moieties A and B are defined above with respect to the first, second, and third aspects of the present invention.

[0100] In an example embodiment of the seventh aspect of the present invention, the moiety D, for each occurrence independently, is selected from List D4, List D5, or both.

##STR00036## ##STR00037## ##STR00038## ##STR00039## ##STR00040## ##STR00041## ##STR00042## ##STR00043## ##STR00044##

wherein, within each molecule:

[0101] Q is independently selected from the group consisting of the moiety A, a moiety B.sub.0-2-A, H, C.sub.1-C.sub.3 alkyl, C.sub.6-C.sub.18 aryl, oxo, (5-20 atom) heteroaryl, and N(C.sub.6-C.sub.18 aryl).sub.2, and wherein

[0102] A is defined above with respect to the first, second, and third aspects of the present invention.

[0103] In an example embodiment of the seventh and eighth aspects of the present invention, the moiety D, for each occurrence independently, can also be selected from List D6.

##STR00045## ##STR00046## ##STR00047## ##STR00048## ##STR00049## ##STR00050## ##STR00051## ##STR00052## ##STR00053##

wherein, within each molecule:

[0104] Q is independently selected from the group consisting of the moiety A, a moiety B.sub.0-2-A, H, C.sub.1-C.sub.3 alkyl, C.sub.6-C.sub.18 aryl, oxo, (5-20 atom) heteroaryl, and N(C.sub.6-C.sub.18 aryl).sub.2,

[0105] M is independently selected from the group consisting of the moiety A, a moiety B.sub.02-A, H, C.sub.1-C.sub.3 alkyl, C.sub.6-C.sub.18aryl, oxo, (5-20 atom) heteroaryl, and N(C.sub.6-C.sub.18 aryl).sub.2,

[0106] at least one of Q and M is the moiety B.sub.0-2-A,

[0107] all groups Q are the same and all groups M are the same, and

[0108] each group Q is the same or different from any group M, and wherein A is defined above with respect to the first, second, and third aspects of the present invention.

[0109] In an example embodiment of the ninth aspect of the present invention, the moiety A, for each occurrence independently, is selected from List A4.

##STR00054## ##STR00055## ##STR00056## ##STR00057##

wherein, within each molecule:

[0110] W is the moiety D or a moiety B.sub.0-2-D and each X is the moiety D or the moiety B.sub.0-2-D,

[0111] all groups W are the same and all groups X are the same, and

[0112] each group W is the same or different from any group X, and wherein D is defined above with respect to the first, second, and third aspects of the present invention.

[0113] In an example embodiment of the tenth aspect of the present invention, the moiety A, for each occurrence independently, can be selected from List A4, List A5, or both.

##STR00058## ##STR00059## ##STR00060## ##STR00061## ##STR00062## ##STR00063## ##STR00064## ##STR00065##

wherein, within each molecule:

[0114] X is selected from the group consisting of the moiety D, a moiety B.sub.0-2-D, H, C.sub.1-C.sub.3 alkyl, C.sub.6-C.sub.18 aryl oxo, C.sub.1-C.sub.3 haloalkyl, CF.sub.3, C(O)C.sub.1-C.sub.3 haloalkyl, F, and S(O.sub.2)H, and

[0115] D is defined as above with respect to the first, second, and third aspects of the present invention.

[0116] In an example embodiment of the tenth and eleventh aspects of the present invention, the moiety A, for each occurrence independently, can be selected from List A4, List A5, List A6, or any combination thereof.

##STR00066## ##STR00067## ##STR00068## ##STR00069## ##STR00070## ##STR00071## ##STR00072## ##STR00073##

wherein, within each molecule:

[0117] X is selected from the group consisting of a moiety B.sub.0-2-D, H, C.sub.1-C.sub.3 alkyl, C.sub.6-C.sub.18 aryl oxo, C.sub.1-C.sub.3 haloalkyl, CN, CF.sub.3, C(O)C.sub.1-C.sub.3 haloalkyl, F, and S(O.sub.2)H,

[0118] W is selected from the group consisting of the moiety B.sub.0-2-D, H, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 acylalkyl, C.sub.6-C.sub.18aryl, oxo, C.sub.1-C.sub.3 haloalkyl, CN, CF.sub.3, C(O)C.sub.1-C.sub.3 haloalkyl, F, and S(O.sub.2)H,

[0119] at least one of W and X is the moiety B.sub.0-2-D,

[0120] all groups W are the same and all groups X are the same, and

[0121] each group W is the same or different from any group X, and wherein D is as defined above with respect to the first, second, and third aspects of the present invention.

[0122] In a twelfth aspect, the present invention is a molecule as defined above with respect to the first or second aspects of the present invention, and A and D are, for each occurrence independently, selected from list U1, U2, U3, U4, U5, U6, U7, U8 or U9; and further wherein D, for each occurrence independently, is optionally substituted with one or more substituents each independently selected from C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.6-C.sub.18 aryl, (5-20 atom) heteroaryl, C.sub.1-C.sub.6 alkoxy, amino, C.sub.1-C.sub.3 alkylamino, C.sub.1-C.sub.3 dialkylamino, or oxo; A, for each occurrence independently is optionally substituted with one or more substituents independently selected from C.sub.6-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.6-C.sub.18 aryl, (5-20 atom) heteroaryl, C.sub.1-C.sub.6 alkoxy, C(O)C.sub.1-C.sub.3 haloalkyl, S(O.sub.2)H, NO.sub.2, CN, oxo, halogen, or C.sub.6-C.sub.18 haloaryl, and B, for each occurrence independently, is optionally substituted with one or more substituents selected from C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.6-C.sub.18 aryl, (5-20 atom) heteroaryl C.sub.1-C.sub.6.

##STR00074## ##STR00075## ##STR00076## ##STR00077## ##STR00078## ##STR00079## ##STR00080## ##STR00081## ##STR00082## ##STR00083## ##STR00084## ##STR00085## ##STR00086##

[0123] In some embodiments of the twelfth aspect, A and D are selected from list and B is:

##STR00087##

[0124] In further embodiments of the twelfth aspect, the present invention is a molecule selected from the following structural formulas:

##STR00088##

[0125] In some embodiments of the twelfth aspect, A and D are selected from list U2, and B is:

##STR00089##

[0126] In further embodiments of the twelfth aspect, the present invention is a molecule selected from the following structural formulas:

##STR00090##

[0127] In some embodiments of the twelfth aspect, A and D are selected from list U3, and B is:

##STR00091##

[0128] In further embodiments of the twelfth aspect, the present invention is a molecule selected from the following structural formulas:

##STR00092##

[0129] In some embodiments of the twelfth aspect, A and D are selected from list U4, and B is:

##STR00093##

[0130] In further embodiments of the twelfth aspect, the present invention is a molecule selected from the following structural formulas:

##STR00094##

[0131] In some embodiments of the twelfth aspect, A and D are selected from list U5, and B is:

##STR00095##

[0132] In further embodiments of the twelfth aspect, the present invention is a molecule selected from the following structural formulas:

##STR00096##

[0133] In some embodiments of the twelfth aspect, A and D are selected from list U6, and B is:

##STR00097##

[0134] In further embodiments of the twelfth aspect, the present invention is a molecule selected from the following structural formulas:

##STR00098## ##STR00099##

[0135] In some embodiments of the twelfth aspect, A and are selected from list U7, and B is:

##STR00100##

[0136] In further embodiments of the twelfth aspect, the present invention is a molecule selected from the following structural formulas:

##STR00101## ##STR00102## ##STR00103## ##STR00104##

[0137] In some embodiments of the twelfth aspect, A and D are selected from list U8, and B is:

##STR00105##

[0138] In further embodiments of the twelfth aspect, the present invention is a molecule selected from the following structural formulas:

##STR00106## ##STR00107## ##STR00108##

[0139] In some embodiments of the twelfth aspect, A and D are selected from list U9, and B is:

##STR00109##

[0140] In further embodiments of the twelfth aspect, the present invention is a molecule selected from the following structural formulas:

##STR00110## ##STR00111## ##STR00112##

[0141] In some embodiments of the twelfth aspect, A and D are selected from list U10, and B is:

##STR00113##

[0142] In further embodiments of the twelfth aspect, the present invention is a molecule selected from the following structural formulas:

##STR00114##

[0143] In some embodiments of the twelfth aspect, the molecule is selected from Table 1:

TABLE-US-00001 TABLE 1 [00115] [00116] [00117] [00118] [00119] [00120] [00121] [00122] [00123] [00124] [00125] [00126] [00127] [00128] [00129] [00130] [00131] [00132] [00133] [00134] [00135] [00136] [00137] [00138] [00139] [00140] [00141] [00142] [00143] [00144] [00145] [00146] [00147] [00148] [00149] [00150] [00151] [00152] [00153] [00154] [00155] [00156] [00157] [00158] [00159] [00160] [00161] [00162] [00163] [00164] [00165] [00166] [00167] [00168] [00169] [00170] [00171] [00172] [00173] [00174] [00175] [00176] [00177] [00178] [00179] [00180] [00181] [00182] [00183] [00184] [00185] [00186]

[0144] In an example embodiment of any one of the first through twelfth aspects of the present invention described above, the moiety D is optionally substituted with one or more substituents each independently selected from C.sub.1-C.sub.3 alkyl, C.sub.6-C.sub.18 aryl, or oxo, and wherein A, B, and D are defined above with respect to the first or second aspects of the present invention.

[0145] In an example embodiment of any one of the first through twelfth aspects of the present invention described above, the moiety D is optionally substituted with one or more substituents each independently selected from (5-20 atom) heteroaryl or N(C.sub.6-C.sub.18aryl).sub.2, and

wherein A, B, and D are defined above with respect to the first or second aspects of the present invention.

[0146] In an example embodiment of any one of the first through twelfth aspects of the present invention described above, the moiety D is optionally substituted with one or more substituents each independently selected from C.sub.1-C.sub.3 alkyl, C.sub.6-C.sub.18 aryl, oxo, (5-20 atom) heteroaryl, or N(C.sub.6-C.sub.18aryl).sub.2, and wherein A, B, and D are defined above with respect to the first or second aspects of the present invention.

[0147] In an example embodiment of any one of the first through twelfth aspects of the present invention described above, the moiety A is optionally substituted with one or more substituents each independently selected from C.sub.1-C.sub.3 alkyl, C.sub.6-C.sub.18 aryl, oxo, C.sub.1-C.sub.3 haloalkyl, CN, CF.sub.3, C(O)C.sub.1-C.sub.3 haloalkyl F, and S(O.sub.2)H, and wherein A, B, and D are defined above with respect to the first or second aspects of the present invention.

[0148] In an example embodiment of any one of the first through twelfth aspects of the present invention described above, the moiety B2 is optionally substituted with C.sub.1-C.sub.3 alkyl, and wherein A, B, and D are defined above with respect to the first or second aspects of the present invention.

[0149] In an example embodiment of any one of the first through twelfth aspects of the present invention described above, the moiety B is optionally substituted with C.sub.6-C.sub.18 aryl, and wherein A, B, and D are defined above with respect to the first or second aspects of the present invention.

[0150] In an example embodiment of any one of the first through twelfth aspects of the present invention described above, the moiety B is optionally substituted with one or more substituents each independently selected from C.sub.1-C.sub.3 alkyl or C.sub.6-C.sub.18 aryl, and wherein A, B, and D are defined above with respect to the first or second aspects of the present invention.

[0151] In a thirteenth aspect, the present invention is a molecule of one of the structural formulas represented in Table 1.

[0152] In a fourteenth aspect, the present invention is a molecule of one of the structural formulas represented in Table 3, wherein any substitutable position (i.e., any position where a hydrogen atom is attached) is optionally substituted by a C.sub.1-C.sub.6 alkyl, OH, CN, a halo, a C.sub.6-C.sub.12 aryl, a 5-20 atom heteroaryl, N(R.sup.19).sub.2, or N(R.sup.20).sub.2, wherein each R.sup.19, independently, is H or a C.sub.1-C.sub.6 alkyl, or a C.sub.5-C.sub.12 cycloalkyl, and wherein each R.sup.20, independently, is H or a C.sub.6-C.sub.18 aryl. Preferably, substitutable positions are unsubstituted or substituted with C.sub.1-C.sub.6 alkyl or phenyl.

[0153] In exemplary embodiments of the fourteenth aspect, the present invention is a molecule of one of the structural formulas represented in Table 1, wherein any substitutable position (i.e., any position where a hydrogen atom is attached) is optionally substituted by a C.sub.1-C.sub.6 alkyl, OH, CN, a halo, a C.sub.6-C.sub.12 aryl, a 5-20 atom heteroaryl, N(R.sup.19).sub.2, or N(R.sup.20).sub.2, wherein each R.sup.19, independently, is H or a C.sub.1-C.sub.6 alkyl, or a C.sub.5-C.sub.12 cycloalkyl, and wherein each R.sup.20, independently, is H or a C.sub.6-C.sub.18 aryl. Preferably, substitutable positions are unsubstituted or substituted with C.sub.1-C.sub.6 alkyl or phenyl.

[0154] In example embodiments of the fourteenth aspect, the present invention is one of the molecules depicted in Table 2.

TABLE-US-00002 TABLE 2 [00187] [00188] [00189] [00190] [00191] [00192] [00193] [00194] [00195] [00196] [00197] [00198] [00199] [00200] [00201] [00202] [00203] [00204] [00205] [00206] [00207] [00208] [00209] [00210] [00211] [00212] [00213] [00214] [00215] [00216] [00217] [00218] [00219] [00220] [00221] [00222] [00223] [00224] [00225] [00226] [00227] [00228] [00229] [00230] [00231] [00232] [00233] [00234] [00235] [00236] [00237] [00238] [00239] [00240] [00241] [00242] [00243] [00244] [00245] [00246] [00247] [00248] [00249] [00250] [00251] [00252] [00253] [00254] [00255] [00256] [00257] [00258] [00259] [00260] [00261]

[0155] For the molecules depicted in Table 2, X is C.sub.1-C.sub.6 alkyl, OH, CN, a halo, a C.sub.6-C.sub.12 aryl, a 5-20 atom heteroaryl, N(R.sup.19).sub.2, or N(R.sup.20).sub.2, wherein each R.sup.19, independently, is H or a C.sub.1-C.sub.6 alkyl, or a C.sub.5-C.sub.12 cycloalkyl, and wherein each R.sup.20, independently, is H or a C.sub.6-C.sub.18 aryl. Preferably, X is C.sub.1-C.sub.6 alkyl or phenyl.

[0156] In an example embodiment of any one of the aspects of the present invention described above, the moiety A and the moiety D are different.

[0157] In an example embodiment of any one of the aspects of the present invention described above, the moiety D has a highest occupied molecular orbital (HOMO) energy above 6.5 eV and the moiety A has a lowest unoccupied molecular orbital (LUMO) energy below 0.5 eV.

[0158] In an example embodiment of any one of the aspects of the present invention described above, the molecule is group symmetric or synthetic symmetric.

Combinatorial Assembly and Screening

[0159] Example molecules of the present invention having desirable properties, such as color of visible emission, can be constructed from the acceptor, donor, and bridge moieties described above using a combinatorial process described below. While only a few example compounds are illustrated below, it is understood that different combinations of different moieties can be used to create a combinatorial library of compounds. The example moieties below are intended only to illustrate the concepts herein, and are not intended to be limiting.

[0160] In the first step, a library of chemical moieties are screened for their abilities to function as acceptor or donor moieties. Example properties examined include desirable quantum mechanical computations such as the ionization potential of the highest occupied molecular orbital (i.e., a donor moiety) and the electron affinity of the lowest unoccupied molecular orbital (i.e., an acceptor moiety). In an example embodiment, a donor moiety can be selected if it is calculated that it has an ionization potential of greater than or equal to 6.5 eV. In another example embodiment, an acceptor moiety can be selected if it is calculated that it has an electron affinity of less than or equal to 0.5 eV. An example donor moiety selected after screening could be:

##STR00262##

and an example acceptor moiety selected after screening could be:

##STR00263##

wherein (*) represents a point of attachment for the donor and acceptor moieties either to each other or to a bridge moiety.

[0161] In a second, optional, step, if the selected donor and/or acceptor is multi-site, the multi-site donor moiety is combined with a single-site bridge moiety, and/or the multi-site acceptor moiety is combined with a single-site bridge moiety. If the donor and/or acceptor moieties are single-site moieties, then multi-site bridge moieties can be combined with the selected moieties. For the purposes of the combinatorial assembly, the number of sites refers to how many potentially different moieties can be attached. For example, the moiety below has one site:

##STR00264##

because all moieties attached at the position labeled Q must be the same. Similarly, the moiety below has two sites because Q and M can be the same or different:

##STR00265##

Thus, the nitrogen atom in the molecule is multi-site.

[0162] In the example moieties from the first step, both moieties are single-site. An example multi-site bridge could be:

##STR00266##

wherein the moieties attached at Y and Z are different. If the donor moiety combines with a bridge, and the acceptor combines with a bridge, the following moieties are created:

##STR00267##

[0163] In a third step, the second step can be repeated to continuously add bridge moieties to the molecule. The only limitation is the size of final molecules that are going to be generated. The bridge molecules can be added at position Y or Z, indicated above, and can be the same bridge moiety, or a different bridge moiety. In one example embodiment, the number of bridge moieties can be limited to a number between 0 and 3. In another example, the number of donor moieties and acceptor moieties, or the total molecular weight of the molecule can be limited. In an example embodiment, the molecules are symmetrical. The symmetry can be used to limit the molecules in the combinatorial process to those that are stable. Therefore, for example, an additional bridge moiety added to the moieties from step two could be:

##STR00268##

[0164] In a fourth step, the unattached point on the bridge moieties only combine with either (1) a donor moiety or an acceptor moiety that does not have a bridge moiety attached; or (2) other bridge moieties that is attached to either an acceptor moiety or a donor moiety such that the size limitation in step three is not violated, and that each molecule comprises at least one donor moiety and one acceptor moiety.

[0165] Using the example moieties and the rules described above, the following example molecules can be created:

##STR00269## ##STR00270## ##STR00271##

[0166] In the fifth step, the combined potential donors, acceptors, and bridges can be screened based on quantum mechanical computations such as desired HOMO and LUMO values, as well as vertical absorption (the energy required to excite the molecule from the ground state to the excited state), rate of decay (S1 to S0 oscillator strength, e.g., how fast and/or how bright the molecule's emission after excitation), estimated color of visible light emission in nanometers, and the singlet-triplet gap (the energy difference between the lowest singlet excited state, S1, the lowest triplet excited state, T1). Examples of the results of such calculations obtained for the molecules exemplified in the present application are provided in FIGS. 1-19, which represent Table 3.

[0167] Additional donors, bridges, and acceptors, as well as generally applicable methods of synthesis, are discussed in WO2015175680A1.

Exemplification

[0168] It is understood that substituents and substitution patterns on the compounds of the invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art, as well as those methods set forth in Theophil Eicher, et al., The Chemistry of Heterocycles: Structures, Reactions, Synthesis, and Applications, which is incorporated herein by reference in its entirety.

EXAMPLE 1

Preparation of 10-phenyl-4a,9a-dihydro-10H, 10H-spiro[acridine-9,9-anthracen]-10-one

[0169] An exemplary synthesis is represented by the following reaction scheme:

##STR00272##

[0170] In this exemplary synthesis, n-BuLi (1.6 M in hexane, 14.6 mL, 23.3 mmol) is added to a solution of of 2-bromotriphenylamine (7.54 g, 23.3 mmol) in dry THF (180 mL) at 78 C. That mixture is stirred for 1.5 hours at 78 C. Anthraquinone (4.3 g, 21.2 mmol) is added to the reaction solution, which is then stirred for 1 day at 0 C. The reaction mixture is extracted into chloroform. The organic layer is dried over MgSO.sub.4, filtered, and concentrated in vacuo, then purified by column chromatography. The reaction product (3.21 g, 7.09 mmol), acetic acid (55 mmol), and HCl (5.5 mL) are stirred for 4 hours under reflux. The reaction mixture is filtered, and the product is extracted into chloroform. The organic layer is dried over MgSO.sub.4, filtered, and concentrated in vacuo, then purified by column chromatography.

EXAMPLE 2

Preparation of 3-(1,6-naphthyridin-8-yl)-N,N-diphenyladamantan-1-amine

[0171] 3-(1,6-naphthyridin-8-yl)-N,N-diphenyladamantan-1-amine may be prepared by a person of ordinary skill by the following scheme:

##STR00273##

See Chem. Commun. (Cambridge), 47 4778-4780; J. Org. Chem., 64 (16), 6019-6022. The starting materials may be purchased, for example, from Sigma Aldrich, Ark Pharm, Alfa Aesar, or eMolecules.

EXAMPLE 3

Preparation of 5-((4R,5R)-5-(4-(9H-pyrido[3,4-b]indol-9-yl)phenyl)-2,2-dimethyl-1,3-dioxolan -4-yl)isophthalonitrile

[0172] 5-((4R,5R)-5-(4-(9H-pyrido[3,4-b]indol-9-yl)phenyl)-2,2-dimethyl-1,3-dioxolan-4-yl)isophthalonitrile may be prepared by a person of ordinary skill by the following scheme:

##STR00274##

See Tetrahedron Lett., 45 (42), 7873-7877; Synthesis, (20), 3493-3503; Angew. Chem, Int. Ed., 51 (38),9581-9586; Synthesis, (10), 1263-1266; Angew. Chem., Int. Ed., 53 (13), 3505-3509. The starting materials may be purchased, for example, from Sigma Aldrich, Alfa Aesar, or eMolecules.

EXAMPLE 4

Preparation of 3,5-bis(3-(4-(diphenylamino)phenyl)bicyclo[1.1.1]pentan-1-yl)-[1,1-biphenyl]-3,5-dicarbonitrile

[0173] 3,5-bis(3-(4-(diphenylamino)phenyl)bicyclo[1.1.1]pentan-1-yl)-[1,1-biphenyl]-3,5-dicarbonitrile may be prepared by a person of ordinary skill by the following scheme:

##STR00275##

See J. Am. Chem. Soc., 136 (38), 13194-13197; Chem-Eur. J., 11 (8), 2483-2492; Angew. Chem., 105(4), 647-649; Org. Lett., 13 (5), 1001-1003, Org. Lett., 15 (7), 1634-1637; J. Am. Chem. Soc., 132 (27), 9292-9294; Synlett., (6), 539-541. The starting materials may be purchased, for example, from Sigma Aldrich, Alfa Aesar, or eMolecules.

EXAMPLE 5

Preparation of 8-(2-(1H-pyrrolo[3,2-c]pyridin-1-yl)cyclopropyl)pyrido[3,4-b]pyrazine

[0174] 5-((4R,5R)-5-(4-(9H-pyrido[3,4-b]indol-9-yl)phenyl)-2,2-dimethyl-1,3-dioxolan-4-yl)isophthalonitrile may be prepared by a person of ordinary skill by the following scheme:

##STR00276##

See Org. Lett., 7 (6), 1169-1172; Synthesis, (11), 1683-1696; Tetrahedron Lett., 51 (28), 3623-3625; Angew. Chem. Int Ed., 52 (38), 10060-10063; Synth Commun., 38 (2), 162-169; Perkin 1 (17), 2012-2021; Monatsch. Chem., 142 (11), 1193-1201. The starting materials may be purchased, for example, from Sigma Aldrich, Alfa Aesar, or eMolecules. eMolecules.

EXAMPLE 6

Preparation of 2,2,2-((6-(3-(benzofuro[2,3-b]pyridin-7-yl)phenyl)bicyclo[2.2.2]oct-2-ene-2,3,5-triyl)tris(methaneylylidene))trimalononitrile

[0175] 2,2,2-((6-(3-(benzofuro[2,3-b]pyridin-7-yl)phenyl)bicyclo[2.2.2]oct-2-ene-2,3,5-triyl)tris(methaneylylidene))trimalononitrile may be prepared by a person of ordinary skill by the following scheme:

##STR00277## ##STR00278##

See Tetrahedron, 59 (18), 3283-3290; Synlett, (17), 2593-2596; J. Heterocyclic Chem., 42 (7), 1409-1411; Chem. Commun. (Cambridge), (22), 2568-2569; Bull. Chem. Soc. Jpn., 68 (11), 3137-3143; Tetrahedron Lett., 42 (15), 2783-2785; Zh. Org. 27(5), 1121-1122; Izv. Akad. Nauk., Ser Khim, (11) 2722-2725; Tetrahedron Lett., 46 (50), 8711-8714; J. Am. Chem. Soc., 130 (46), 15248-15249; Tetrahedron, 58 (47), 9527-9540; Synlett, (1), 67-68; J. Comb. Chem., 11 (3), 508-514; Indian J. Chem., Sect. B, 49(2), 247-250. The starting materials may be purchased, for example, from Sigma Aldrich, Alfa Aesar, or eMolecules.

[0176] The teachings of all patents, published applications and references cited herein are incorporated by reference in their entirety.

[0177] While this invention has been particularly shown and described with references to example embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.